Intranasal absorption of a kappa agonist analgesic.
Hussain
M A
MA
CNS Diseases Research, Du Pont Merck Pharmaceutical Co., Wilmington, Delaware 19880.
Schmidt
W K
WK
Buehler
J D
JD
D000042:Absorption; D000281:Administration, Intranasal; D000700:Analgesics / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D000818:Animals; D044482:Benzeneacetamides; D001682:Biological Availability; D006207:Half-Life; D008297:Male; D051379:Mice; D009297:Nasal Mucosa / Q000378:metabolism*; D010147:Pain Measurement / Q000187:drug effects; D011759:Pyrrolidines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000187:drug effects*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology
D000700:Analgesics; D044482:Benzeneacetamides; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D013764:Tetrahydronaphthalenes; C083309:E 3800